- Akzo Nobel NV intends to file for worldwide approval of its vaginal contraceptive ring in the near future. Placed near the cervix, this ring releases progesterone and estrogen and provides contraception for several weeks. Akzo hopes that the device will offset problems encountered with its contraceptive pills in the UK and Germany (Marketletters passim). The firm is looking for a launch in the year 2000.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze